Long-Term Antibody Responses to *Vibrio cholerae* Across Natural Infection, Vaccination, and Challenge: A Systematic Review

Running Head: Cholera Antibody Responses Across Exposure Types

Aparna Mangadu[1*], Christy Clutter[1], Kenadee Jacobson[1], Tatum Heiner[1], Shubhanshi Trivedi[1], Md. Saruar Bhuiyan [1], Ben J Brintz[2], Andrew S. Azman[3-5], Benjamin F. Arnold[6], Daniel T. Leung[1,7]

[1] Division of Infectious Diseases, Department of Internal Medicine, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA
[2] Division of Epidemiology, Department of Internal Medicine, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA
[3] Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
[4] Institute of Global Health, University of Geneva, Geneva, Switzerland
[5] Division of Tropical and Humanitarian Medicine and Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.
[6] Francis I. Proctor Foundation and Department of Ophthalmology, University of California, San Francisco, San Francisco, California, USA
[7] Division of Microbiology and Immunology, Department of Pathology, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA

*Corresponding Author: Tel: +1 915-412-8055; E-mail: aparna.mangadu@utah.edu

Word Count: 2,366/3,000
Abstract Word Count: 241/250

Abstract

Background: Cholera is a critical global health threat, with significant impact on low- and middle-income countries. Clinical surveillance is limited by non-specific symptoms, dependence on care-seeking, and availability of microbiological diagnostics, making burden estimation difficult. Serosurveillance is a potential solution, but the design and interpretation of cross-sectional seroepidemiological studies are currently limited by a lack of knowledge of longitudinal antibody trajectories.

Methods: We systematically reviewed literature from 1980 to 2025 containing longitudinal antibody measurements in humans following exposure to *Vibrio cholerae O1/O139* and associated vaccines.

Results: 51 studies representing adults and children from 1 low-income (1 study), 5 lower-middle-income (24 studies), 3 upper-middle-income (5 studies) and 5 high-income (21 studies) countries were included. 16 studies followed natural infection, 36 involved vaccination, and 6 were human challenge models, with some overlap. Antibody responses following infection were significantly higher than those induced by vaccination, particularly against O-specific polysaccharide (OSP). Younger children exhibited higher peak fold-change IgA responses to Cholera-toxin B-subunit (CTB) than older children and adults across infection and vaccine studies. Following vaccination, individuals from high-income countries showed higher IgA, IgG, and vibriocidal fold-change responses compared to those from lower-income settings. Limited data from challenge studies revealed slower decay of IgG compared to IgA and IgM.

Conclusions: This review enhances our understanding of longitudinal immune responses to *V. cholerae*, highlighting variability in antibody kinetics across age groups, geographic regions, and study designs, and informs the design and interpretation of seroepidemiological studies of cholera.

Key Messages:

- Our Research Question: We aimed to systematically review longitudinal antibody responses in humans following natural infection, vaccination, or challenge with *Vibrio cholerae* O1/O139, to inform interpretation of cross-sectional seroepidemiologic studies.

- What We Found: We found that antibody responses vary significantly by exposure type, age group, and geographic setting, with infection inducing stronger and longer-lasting responses than vaccination, and younger children showing higher IgA responses to CTB compared to older children and adults.

- Why it is Important: These findings highlight variability in immune responses across populations and underscore the need for tailored approaches to accurately estimate cholera burden and guide global control strategies.

Introduction

Seroepidemiology investigations use immunological markers from blood, primarily antibodies, which can be measured from population-based sampling and used to estimate population-wide infection burden and immunity following vaccination or natural infection[1]. Serosurveys could be an important tool for monitoring disease prevalence and transmission, identifying gaps in vaccine distribution or adherence, and strategizing public health interventions[2,3]. Despite its growing importance, a critical aspect of seroepidemiology is the need to examine the long-term kinetics of antibody responses to inform interpretations of single time-point measurements from individuals and populations in cross-sectional serosurveys.

Cholera remains a significant public health challenge, responsible for up to 4 million cases and 150,000 deaths annually[4,5]. Cholera particularly impacts those living in low- and middle-income countries due to inadequate health infrastructure, contaminated food and water sources, and insufficient disease surveillance and monitoring systems[6]. Clinical manifestations of *V. cholerae* infection vary from asymptomatic to severe acute watery diarrhea and vomiting, which can lead to severe dehydration and death due to hypovolemic shock[5]. The number of medically-attended cases likely represents only a small proportion of total infections, and serosurveillance, while not measuring clinical disease directly, offers a potential avenue for more accurate burden estimates[7]. However, interpretation of cross-sectional serosurveillance studies relies on modeling of antibody decay kinetics, which may differ depending on the population's geographic location, age structure, and socioeconomic conditions. Additionally, specific to cholera seroepidemiology, a key question is whether antibody kinetics from one region, such as hyperendemic countries in Asia, can be generalizable to other regions, such as non-endemic countries, or endemic countries with infrequent outbreaks. Compiling data on long-term antibody

persistence, or lack thereof, following *V. cholerae* exposure, across exposures, age groups, and

socioeconomic conditions, can inform public health efforts against cholera worldwide.

This systematic review aims to collate and synthesize existing literature on global long-

term antibody kinetics in humans following exposure to *V. cholerae*, with the goal of informing

future seroepidemiological investigations and public health interventions.

Methodology

Overview

We conducted a systematic review to analyze existing literature that report on

longitudinal antibody responses in humans after exposure to *Vibrio cholerae* through natural

infection, vaccination, or controlled human challenge studies. Our methodology for this review

was guided by the established systematic review framework developed by Khan and

colleagues[10], providing a structured approach for mapping key concepts and gaps in literature.

We conducted this review in four key stages: 1) identifying relevant studies through a

comprehensive search of databases, 2) screening and selecting studies for full-text review based

on specific inclusion and exclusion criteria (**Table 1**), 3) extracting relevant data from the

included studies, and 4) collating, summarizing, and reporting the findings to highlight trends,

patterns, knowledge gaps, and areas for future investigation related to long-term antibody

kinetics.

108
Search Strategy

We conducted a systematic literature search using the PubMed and Embase databases to

identify relevant articles. Our search strategy included phrases created using specific key words:

1. Cholera, 2. Vibrio cholerae, 3. Antibody, and 4. Human. These terms were combined using

Boolean operators to conduct search phrases such as '["2" OR 1] AND 3' and '["2" OR 1] AND

3 AND MeSH Terms [4]', where numbers correspond to the key terms listed above. We included

Medical Subject Headings (MeSH) terms to ensure inclusion of articles indexed under

standardized subject headings. We used this strategy to identify articles from the earliest

available time up to and including April 2025. A total of 4,346 articles were identified and

exported to Covidence online software where duplicates were removed.

<u>Selection Criteria, Data Management, and Extraction</u>

We used the Covidence online platform for screening, full text review, and data

extraction. After duplicates were removed, 2,179 articles were available for title and abstract

screening. We reviewed articles based on specific inclusion and exclusion criteria (**Table 1**).

Two independent reviewers (MSB & ST or ST & AM) completed title and abstract

screening using the inclusion criteria to ensure relevant studies were included for full-text

review. We resolved any differences or discrepancies in inclusion/exclusion decisions between

the two reviewers with discussion and consensus. Next, one independent reviewer (CC or AM)

completed full-text reviews of included studies using the same inclusion and exclusion criteria

(**Table 1**). Included studies from full-text reviews were then moved into the data extraction step.

To ensure extraction of relevant data and to streamline the process, a data extraction template

(**Supplementary Table 1**) was created by AM within the Covidence platform. The extraction

template was used by two independent reviewers (AM & KJ or AM & TH) to gather and

consolidate relevant data including: study design, country, country income status and

intervention type. Income status was determined based on the most recent classifications by the

World Bank. The extracted population-specific data included: inclusion and exclusion criteria,

group differences, number of subjects, and population age. Finally, for each outcome measure,

we extracted antibody titers at baseline, peak, and end of study, and seroconversion information

as available. The independent reviewers who performed data extraction made antibody titer

estimations and calculations based on information presented in the main text and figure captions.

To reduce subjective bias, these extractions were compared and refined based on values derived

with the online AI application, PlotDigitizer.

Table 1. Inclusion and Exclusion Criteria

Study Characteristics	Inclusion Criteria	Exclusion Criteria
Study Design	Randomized and non-randomized Case only or case-control Acute and convalescent Pre-vaccine/post-vaccine Pre-challenge/post-challenge Point source outbreak with longitudinal follow up	Descriptive report or case-report without longitudinal follow-up Prevalence, diagnostic, prognostic, or comparison study Trial protocol Only *in vitro* measurement
Publication	Peer reviewed journal Published in English Abstract and full-text available	Any academic dissertation Conference proceedings, abstract, or poster Any pre-print
Pathogen	*Vibrio cholerae O1/O139*	Any other pathogen
Specimen	Serum or Plasma	Any other specimen
Participants	Humans of all ages	Non-human studies
Interventions	Natural Infection Vaccine Trial Challenge Model	Any other type of exposure or unable to determine exposure event
Outcome Measures	Longitudinal antibody and/or vibriocidal titers (follow-up $\geq$ 28 days post onset of symptoms, final vaccine dose, or challenge event)	Antibody and vibriocidal titers not reported and/or no longitudinal follow-up

<u>Analysis</u>

Extracted data were exported as a csv file and imported into R (Version 4.4.1) for

analysis. Population sample sizes corresponding to each extracted value were used to calculate

weighted means and associated confidence intervals. Because of the variability in measurement

scales and units across studies, analyses focused on the fold change in the titer relative to

baseline values. Fold change was defined as the ratio of the titer at each timepoint to the baseline

titer. As these data were heavily right-skewed, weighted means and confidence intervals were

estimated using nonparametric bootstrapping with 5,000 iterations. Using this bootstrapping

approach, we estimated weighted mean peak titer fold changes for each antigen (e.g., OSP, LPS,

CTB), stratified by isotype and intervention type. Additionally, we applied the same method to

assess differences in peak titer fold changes across population age groups and country income

levels. Weighted means of peak titer fold changes between intervention type, antigen, population

age group, and country income type were compared using a one-way weighted ANOVA for

variable with 3 or more independent groups and a two-sample t-test for variables with 2

independent groups using R, *p<0.05.

Results

Study Identification

We reviewed 2,179 abstracts published prior to and including April 2025 (**Figure 1**). Of

those, 166 were selected for full-text review, and data from 51 studies were extracted and

analyzed. Included studies were published between 1980 and 2024.

163
164 **Figure 1.** Flow diagram illustrating the selection of studies included in the systematic review

165
166 A total of 4,346 records were identified through database searches (PubMed and Embase). After removal of 2,167 duplicates,
167 2,179 records underwent title and abstract screening by two independent reviewers, resulting in the exclusion of 2,013 records.
168 Full-text review was conducted for 166 articles, of which 115 were excluded. Data extraction was completed for the remaining
169 51 studies by two independent reviewers. The final dataset included 51 studies: 16 natural infection studies, 36 vaccine studies,
170 and 6 challenge studies.

Figure 2. Sample collection timelines and vaccine dosing schedules across included studies

Each horizontal line represents the timeline for a study (or study group), with blue circles indicating specimen collection timepoints and pink crosses indicating vaccine dosing events (vaccine studies only). Studies are grouped by study type (Challenge, Infection, Vaccine). Multiple rows for a single study denote different dosing or collection groups within that study. The x-axis (square root transformed) displays standardized timepoints from baseline through later follow-up (e.g., day 7, day 14, month 3, year 1, etc.). Grey horizontal lines provide a visual guide to the duration and structure of each study's collection schedule.

The included were categorized into three types of pathogen exposure, 1) natural infection,

2) vaccination, and 3) human challenge model (**Supplementary Table 2**). Vaccine studies were

further categorized into vaccines containing the Cholera Toxin B Subunit (CTB) and those

without CTB. The primary assay used throughout included studies was an enzyme-linked

immunosorbent assay (ELISA). Several studies also used vibriocidal assays. These assays were

used to measure immunoglobulin antibody levels (i.e. IgG, IgA, and IgM) to various antigens

(e.g. LPS, OSP) as well as vibriocidal responses in human serum and/or plasma.

Antigen type significantly influenced peak antibody responses across study types (**Table**

2). Natural infection studies showed significantly higher fold increases in IgG, IgA, and IgM

titers to O-Specific Polysaccharide (OSP) compared to vaccine and challenge studies (IgG: $p =$

0.0019; IgA: $p=0.0004$; IgM: $p = 0.0013$).

Table 2. Weighted Peak Titer Comparisons Across Antigens by Isotype and Study Type

Antigen	N_{eff}[a]	Peak Titer - Fold Change from Baseline [Weighted Mean (95% CI)]
IgG		
Natural Infection		
O-Specific Polysaccharide (OSP)	3.6	5.7 (3.4 – 8.3)
Lipopolysaccharide (LPS)	3.6	2.8 (2.2 – 3.7)
Cholera Toxin B Subunit (CTB)	3.3	4.0 (3.5 – 4.6)
Cholera Toxin (CT)	1.0	12.5
Sialidase	1.0	3.6
Non-CTB Containing Vaccines		
O-Specific Polysaccharide (OSP)	3.4	2.1 (1.2 – 2.7)
Lipopolysaccharide (LPS)	1.9	1.2 (1.1 – 1.3)
CTB-Containing Vaccines		
O-Specific Polysaccharide (OSP)	5.6	1.6 (1.1 – 2.2)
Lipopolysaccharide (LPS)	6.6	2.5 (2.0 – 2.9)
Cholera Toxin B Subunit (CTB)	16.4	6.6 (4.6 – 8.6)
Challenge		
O-Specific Polysaccharide (OSP)	3.9	2.0 (1.2 – 3.2)
Cholera Toxin B Subunit (CTB)	2.4	6.8 (6.2 – 8.3)
Cholera Toxin (CT)	1.0	1.5
Toxin co-regulated pilus A (TcPA)	1.9	1.6 (2.5 – 1.8)

IgA		
Natural Infection		
O-Specific Polysaccharide (OSP)	3.6	13.2 (6.2 – 18.6)
Lipopolysaccharide (LPS)	9.9	12.8 (8.6 – 17.6)
Cholera Toxin B Subunit (CTB)	3.6	10.6 (8.3 – 13.5)
Sialidase	2.0	1.9 (1.1 – 2.7)
Non-CTB Containing Vaccines		
O-Specific Polysaccharide (OSP)	3.3	2.6 (2.0 – 2.9)
Lipopolysaccharide (LPS)	1.9	1.3 (1.3 – 1.4)
CTB-Containing Vaccines		
O-Specific Polysaccharide (OSP)	5.6	2.9 (1.7 – 4.9)
Lipopolysaccharide (LPS)	6.6	3.9 (3.8 – 4.2)
Cholera Toxin B Subunit (CTB)	14.5	13.1 (9.2 – 17.5)
Challenge		
O-Specific Polysaccharide (OSP)	3.9	2.9 (1.6 – 4.7)
Toxin co-regulated pilus A (TcPA)	1.9	1.3 (1.2 – 1.5)
IgM		
Natural Infection		
O-Specific Polysaccharide (OSP)	3.6	6.4 (3.5 – 9.7)
Lipopolysaccharide (LPS)	1.9	3.1 (2.1 – 5.3)
Cholera Toxin B Subunit (CTB)	1.1	1.09 (1.0 – 1.13)
Non-CTB Containing Vaccines		
O-Specific Polysaccharide (OSP)	3.4	1.6 (1.1 – 2.1)
CTB-Containing Vaccines		
O-Specific Polysaccharide (OSP)	5.6	1.8 (1.2 – 2.4)
Lipopolysaccharide (LPS)	1.6	1.9 (0.95 – 2.5)
Cholera Toxin B Subunit (CTB)	2.6	1.2 (1.0 – 1.04)
Challenge		
O-Specific Polysaccharide (OSP)	3.9	2.3 (1.7 – 2.9)
Vibriocidal		
Natural Infection	5.9	96.8 (78.3 – 133.9)
Non-CTB Containing Vaccines	12.0	6.8 (4.7 – 9.8)
CTB-Containing Vaccines	3.4	139.8 (115.0 – 163.0)
Challenge	1.9	8.9 (2.3 – 16.3)

189   [a] Effective Sample Size –defined as $n_{eff} = (\Sigma w_i)^2 / \Sigma w_i^2$. This metric adjusts the raw sample size to reflect information loss due
190   to variation in sampling weights (population sample size) and represents the size of an equivalent simple-random sample

Natural Infection Studies

Among studies involving natural cholera infection (n=16), antibody titers typically peaked between 7- and 30-days after symptom onset, with most reaching their maximum at day 7. All studies involving natural infection were conducted in Bangladesh.

Age related differences were observed in IgA responses with children aged 0-5 years exhibiting higher peak fold increases compared to older children (5-18 years) and adults (**Supplementary Table 3**). This difference was antigen dependent. Peak IgA responses to CTB were significantly greater in children aged 0-5 years than in older age groups ($p = 0.0441$; **Supplementary Table 3**).

Longevity of antibody responses appeared to be influenced by isotype, with IgG having more gradual declines than IgA following peak response. 6 months after natural infection, the latest time point available for studies including children, fold changes from baseline titers were similar between children and adults (**Figure 3b**).

Figure 3. Longitudinal antibody responses in natural infection studies

Longitudinal fold-change antibody responses from eligible natural infection studies are shown and stratified by isotype (IgA, IgG, IgM). **A.** Overall longitudinal trends. **B.** Age-stratified longitudinal trends. Each point represents an individual observation, with point size proportional to the underlying sample size. The dark solid line denotes the weighted mean response, and the shaded region indicates the 95% confidence interval across the 365 days following symptom onset.

Vaccine Studies

A total of 36 vaccination studies were conducted across 14 countries, including Sweden

(*n*=5), the United States (*n*=13), Bangladesh (*n*=9), Thailand (*n*=3), and others (Austria, Haiti,

Colombia, India, Switzerland, Pakistan, Gabon, Australia, Cameroon, and Zambia; one study

each). Vaccines evaluated included formulations containing CTB like Dukoral and Vaxchora,

and vaccines without CTB like Shanchol, administered as single (*n*=19), two-dose (*n*=16), and

three-dose (*n*=7) regimens.

Participants from high-income countries that received a vaccine containing CTB

demonstrated substantially greater fold increases in peak vibriocidal antibody titers compared to

those from upper-middle and lower-middle income countries (**Supplementary Table 4**).

Similarly, IgG and IgA responses targeting the CTB antigen were markedly higher in high-

income settings than lower-middle income countries among participants that received a vaccine

containing CTB. Age also influenced immunogenicity with children aged 5-18 years exhibiting

the highest peak fold increases in vibriocidal antibody responses compared to younger children

and adults ($p < 0.001$; **Supplementary Table 3**). Longitudinal analysis revealed substantial

variability in antibody kinetics across age groups and country income settings (**Supplementary**

Figure 1).

233
Human Challenge Studies

Limited data were available from studies involving exposure to *V. cholerae* through a

human challenge model (*n*=6). Peak antibody titers were observed at 10-, 14-, and 28-days post

challenge. All human challenge models were conducted in adult populations in the United States.

Longitudinal trends indicated that IgG responses peak later than IgA and IgM responses (**Figure**

4).

Figure 4. Longitudinal antibody responses in challenge studies

Longitudinal fold-change antibody responses from challenge studies meeting inclusion criteria are shown and stratified by isotype (IgA, IgG, IgM). Each point represents an individual observation, with point size proportional to the contributing sample size; transparency is applied to enhance visualization of overlapping data. The dark solid line depicts the weighted mean response, and the shaded region represents the 95% confidence interval across the 182 days following the challenge event.

Discussion

Serological surveillance is a promising, underutilized tool for estimating disease burden for bacterial pathogens like *Vibrio cholerae O1/O139*[7,11,12]. This systematic review synthesizes findings from 51 studies to characterize longitudinal antibody kinetics following natural cholera infection, vaccination, or experimental challenge. By examining how antibody responses vary across intervention types, population age, and country income level, this review provides insights that can improve the interpretation of cross-sectional serosurveys and inform public health strategies.

Our analysis shows notable age-related differences in immune responses, particularly for IgA antibodies. Children under 5 years of age exhibited significantly higher peak IgA responses to the CTB antigen following natural cholera infection, but not vaccination, compared to older

children aged 5-18 years and adults, possibly due to lower baseline levels, and/or anamnestic

response due to prior infection with heat-labile enterotoxin B subunit (LTB) of enterotoxigenic

Escherichia coli (ETEC), which share structural and antigenic similarities with CTB[13]. A recent

study similarly identified this trend, reporting substantial increases in IgA and IgG responses to

CTB after infection but not vaccination[14]. Interestingly, older children demonstrated significantly

higher fold changes in vibriocidal responses following vaccination compared to adults.

Importantly, these age-related differences in antibody kinetics suggest that the age structure of a

population must be considered when designing and interpreting serosurveys.

Antibody responses following natural cholera infection were consistently stronger than

those elicited by vaccination, particularly for IgG, IgA, and IgM responses to the OSP antigen.

This finding is consistent with prior studies[14], underscoring the need to further investigate these

differences to reduce seroincidence misclassification and inform other public health

interventions. Further, the persistence of antibody responses varied by isotype in both natural

infection and vaccine studies. As expected, IgG responses showed slower decay than IgA,

presumably reflecting its longer half-life as a result of recycling through neonatal Fc receptor

(FcRn) binding[15]. Vaccine-induced antibody peaks were more variable than those following

natural infection, likely due to differences in vaccine formulation, dosing schedules (**Figure 2**),

and administration routes. These factors complicate interpretation of seroepidemiologic findings

and point to the need for standardized methodologies in vaccine trials.

Participants from high-income countries exhibited significantly higher peak fold-changes

in IgG, IgA, and vibriocidal responses following administration of a vaccine containing CTB

compared to those from lower-income settings. This disparity may reflect differences in baseline

titer levels and health status, exposure history, gut microbiome composition, and nutritional

281 factors[16–18]. These findings also emphasize the importance of considering contextual factors

282 when interpreting vaccine performance across different populations.

283   The findings from this systematic review have several important implications for public

284 health and future immunological investigations. First, there is a clear need for standardized

285 protocols in measuring antibody responses[19], including specific antigen targets and time points

286 for sampling depending on use-case. Second, summarizing longitudinal antibody data can

287 enhance our interpretation of cross-sectional serosurveys by providing critical context on

288 seroprevalence and exposure history for specific populations. This data can help distinguish

289 recent from past exposures and refine population-level disease burden and immunity

290 estimates[19,20]. By characterizing antibody kinetics across age groups, interventions, and

291 geographic settings, these results fill a methodological gap in seroepidemiology to support the

292 development of more accurate and precise cholera burden estimation and transmission models.

293   While this review is comprehensive, there are several limitations to consider. First,

294 several studies utilized figures for presenting antibody titers and concentrations rather than

295 tables. We addressed this limitation by reducing subjective bias with an AI platform as described

296 in the methods. Second, geographic representation was unevenly distributed, with natural

297 infection studies exclusively from Bangladesh and challenge studies only from the United States.

298 Further, challenge studies were only conducted in adult populations, limiting our ability to make

299 comparisons across age groups. Finally, we are unable to make half-life estimations due to

300 variability in antibody reporting between studies including differences in units, measures, and

301 methods of measurement.

Conclusion

Our work demonstrates that antibody responses to *V. cholerae* vary across populations, geographic regions, and interventions. By synthesizing global data on long term antibody kinetics in humans, this review provides a foundation for informing the design of future seroepidemiological studies.

Funding

This work was supported by the National Institutes of Health (R01AI135115 and K24AI166087 to DTL, R01AI162867) and the Dr Thomas D. Rees and Natalie B. Rees Presidential Endowed Chair in Global Medicine (to DTL)

Ethics

This study used ONLY openly available human data derived from peer-reviewed publications identified through systematic searches of bibliographic databases (e.g., PubMed, Embase). All data were publicly available before the initiation of this work.

Data Availability Statement

All data used in this systematic review were extracted from previously published studies. The compiled dataset generated during the review process is available from the corresponding author upon reasonable request.

AI Tool Use Statement

Our use of AI was limited to the use of Plot Digitizer AI for reducing subjective bias in data extraction from figures.

References

1. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol. 2020 May 19;5(47):eabc6347.

2. Arnold BF, Scobie HM, Priest JW, Lammie PJ. Integrated Serologic Surveillance of Population Immunity and Disease Transmission. Emerg Infect Dis. 2018 July;24(7):1188–94.

3. Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, et al. Estimating cholera incidence with cross-sectional serology. Sci Transl Med. 2019 Feb 20;11(480):eaau6242.

4. Cholera [Internet]. [cited 2025 June 6]. Available from: https://www.who.int/health-topics/cholera

5. Kanungo S, Azman AS, Ramamurthy T, Deen J, Dutta S. Cholera. Lancet. 2022 Apr 9;399(10333):1429–40.

6. Asantewaa AA, Odoom A, Owusu-Okyere G, Donkor ES. Cholera Outbreaks in Low- and Middle-Income Countries in the Last Decade: A Systematic Review and Meta-Analysis. Microorganisms. 2024 Dec;12(12):2504.

7. Azman AS, Lauer SA, Bhuiyan TR, Luquero FJ, Leung DT, Hegde ST, et al. Vibrio cholerae O1 transmission in Bangladesh: insights from a nationally representative serosurvey. Lancet Microbe. 2020 Dec;1(8):e336–43.

8. Holmgren J. Modern History of Cholera Vaccines and the Pivotal Role of icddr,b. J Infect Dis. 2021 Dec 20;224(12 Suppl 2):S742–8.

9. Xu H, Tiffany A, Luquero FJ, Kanungo S, Bwire G, Qadri F, et al. Protection from killed whole-cell cholera vaccines: a systematic review and meta-analysis. Lancet Glob Health. 2025 July;13(7):e1203–12.

10. Khan KS, Kunz R, Kleijnen J, Antes G. Five Steps to Conducting a Systematic Review. J R Soc Med. 2003 Mar 1;96(3):118–21.

11. Jones FK, Bhuiyan TR, Slater DM, Ternier R, Hutt Vater KR, Khan AI, et al. Expanding cholera serosurveillance to vaccinated populations. mBio. 2025 Nov 12;16(11):e0189825.

12. Jones FK, Bhuiyan TR, Muise RE, Khan AI, Slater DM, Hutt Vater KR, et al. Identifying Recent Cholera Infections Using a Multiplex Bead Serological Assay. mBio. 2022 Dec 20;13(6):e0190022.

13. Holmgren J, Svennerholm AM. Immunological cross-reactivity betweenEscherichia coli heat-labile enterotoxin and cholera toxin A and B subunits. Current Microbiology. 1979 Jan 1;2(1):55–8.

14. Jones FK, Bhuiyan TR, Slater DM, Ternier R, Hutt Vater KR, Khan AI, et al. Expanding
cholera serosurveillance to vaccinated populations. mBio. 2025 Nov 12;16(11):e0189825.

15. Zakrzewicz A, Vanderheyden K, Galaly Y, Feldhoff S, Sips M, Brinkhaus M, et al. Binding
to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in
keratinocytes. Front Immunol. 2024 Oct 10;15:1473637.

16. Desai SN, Cravioto A, Sur D, Kanungo S. Maximizing protection from use of oral cholera
vaccines in developing country settings. Hum Vaccin Immunother. 2014 June 1;10(6):1457–
65.

17. Parker EP, Ramani S, Lopman BA, Church JA, Iturriza-Gómara M, Prendergast AJ, et al.
Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol. 2018
Jan;13(1):97–118.

18. Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons
from a live cholera vaccine. BMC Biol. 2010 Oct 4;8(1):129.

19. Hay JA, Routledge I, Takahashi S. Serodynamics: A primer and synthetic review of methods
for epidemiological inference using serological data. Epidemics. 2024 Dec 1;49:100806.

20. Davis KL, Nieznanski C, Maisha FM, Brintz BJ, Clutter CH, Alam MT, et al. Long-term
Kinetics of Vibriocidal Antibody Responses After Vibrio cholerae Infection in the
Democratic Republic of Congo. J Infect Dis. 2025 July 22;jiaf382.

Included Studies in Systematic Review

1. Bergquist C, Johansson EL, Lagergård T, Holmgren J, Rudin A. Intranasal vaccination of
humans with recombinant cholera toxin B subunit induces systemic and local antibody
responses in the upper respiratory tract and the vagina. Infect Immun. 1997 Jul;65(7):2676–
84.

2. Cryz SJ, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and immunogenicity of
a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD
103-HgR) vaccine in healthy adults. Infect Immun. 1995 Apr;63(4):1336–9.

3. Jertborn M, Svennerholm AM, Holmgren J. IgG and IgA subclass distribution of antitoxin
antibody responses after oral cholera vaccination or cholera disease. Int Arch Allergy Appl
Immunol. 1988;85(3):358–63.

4. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J. Seroepidemiological
studies of El Tor cholera in Bangladesh: association of serum antibody levels with
protection. J Infect Dis. 1985 Feb;151(2):236–42.

5. Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrera-Oro M, Hyman T, et al. Peru-15, an
improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis. 1995
Oct;172(4):1126–9.

6. Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, et al. Estimating
cholera incidence with cross-sectional serology. Sci Transl Med. 2019 Feb
20;11(480):eaau6242.

7. Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, et al. Anti-O-
specific polysaccharide (OSP) immune responses following vaccination with oral cholera
vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-
type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Negl Trop Dis.
2018 Apr;12(4):e0006376.

8. Uddin T, Harris JB, Bhuiyan TR, Shirin T, Uddin MI, Khan AI, et al. Mucosal Immunologic
Responses in Cholera Patients in Bangladesh. Clin Vaccine Immunol CVI. 2011
Mar;18(3):506–12.

9. Uddin T, Aktar A, Xu P, Johnson RA, Rahman MA, Leung DT, et al. Immune responses to
O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult
Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in
patients with cholera. Am J Trop Med Hyg. 2014 May;90(5):873–81.

10. Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, et al. The Live
Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated
Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae. Clin Vaccine
Immunol CVI. 2017 Jan 5;24(1):e00470-16.

11. Leung DT, Rahman MA, Mohasin M, Patel SM, Aktar A, Khanam F, et al. Memory B cell
and other immune responses in children receiving two doses of an oral killed cholera vaccine
compared to responses following natural cholera infection in Bangladesh. Clin Vaccine
Immunol CVI. 2012 May;19(5):690–8.

12. Leung DT, Rahman MA, Mohasin M, Riyadh MA, Patel SM, Alam MM, et al. Comparison
of Memory B Cell, Antibody-Secreting Cell, and Plasma Antibody Responses in Young
Children, Older Children, and Adults with Infection Caused by Vibrio cholerae O1 El Tor
Ogawa in Bangladesh. Clin Vaccine Immunol CVI. 2011 Aug;18(8):1317–25.

13. Aktar A, Rahman MA, Afrin S, Faruk MO, Uddin T, Akter A, et al. O-Specific
Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and
Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh. Clin Vaccine Immunol CVI.
2016 May;23(5):427–35.

14. Weil AA, Chowdhury F, Khan AI, Leung DT, Uddin T, Begum YA, et al. Frequency of
reexposure to Vibrio cholerae O1 evaluated by subsequent vibriocidal titer rise after an
episode of severe cholera in a highly endemic area in Bangladesh. Am J Trop Med Hyg.
2012 Nov;87(5):921–6.

15. Falkard B, Charles RC, Matias WR, Mayo-Smith LM, Jerome JG, Offord ES, et al. Bivalent
oral cholera vaccination induces a memory B cell response to the V. cholerae O1-
polysaccharide antigen in Haitian adults. PLoS Negl Trop Dis. 2019 Jan 31;13(1):e0007057.

16. Alam MM, Arifuzzaman M, Ahmad SM, Hosen MI, Rahman MA, Rashu R, et al. Study of
Avidity of Antigen-Specific Antibody as a Means of Understanding Development of Long-
Term Immunological Memory after Vibrio cholerae O1 Infection. Clin Vaccine Immunol
CVI. 2013 Jan;20(1):17–23.

17. Kendall EA, Tarique AA, Hossain A, Alam MM, Arifuzzaman M, Akhtar N, et al.
Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-
dependent antigen following infection with Vibrio cholerae O1 in Bangladesh. Infect
Immun. 2010 Jan;78(1):253–9.

18. Jayasekera CR, Harris JB, Bhuiyan S, Chowdhury F, Khan AI, Faruque ASG, et al. Cholera
Toxin–Specific Memory B Cell Responses Are Induced in Patients with Dehydrating
Diarrhea Caused by Vibrio cholerae O1. J Infect Dis. 2008 Oct 1;198(7):1055–61.

19. Czerkinsky C, Svennerholm AM, Quiding M, Jonsson R, Holmgren J. Antibody-producing
cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect
Immun. 1991 Mar;59(3):996–1001.

20. Akter A, Dash P, Aktar A, Jahan SR, Afrin S, Basher SR, et al. Induction of systemic,
mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific
polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell
cholera vaccine in Bangladesh. PLoS Negl Trop Dis. 2019 Aug;13(8):e0007634.

21. Leung DT, Bhuiyan TR, Nishat NS, Hoq MR, Aktar A, Rahman MA, et al. Circulating
mucosal associated invariant T cells are activated in Vibrio cholerae O1 infection and
associated with lipopolysaccharide antibody responses. PLoS Negl Trop Dis. 2014
Aug;8(8):e3076.

22. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. Duration of
infection-derived immunity to cholera. J Infect Dis. 1981 Jun;143(6):818–20.

23. Wasserman SS, Losonsky GA, Noriega F, Tacket CO, Castañeda E, Levine MM. Kinetics of
the vibriocidal antibody response to live oral cholera vaccines. Vaccine. 1994
Aug;12(11):1000–3.

24. Tacket CO, Forrest B, Morona R, Attridge SR, LaBrooy J, Tall BD, et al. Safety,
immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera
hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun. 1990 Jun;58(6):1620–7.

25. Kanungo S, Lopez AL, Ali M, Manna B, Kim DR, Mahapatra T, et al. Vibriocidal antibody
responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata,
India. PloS One. 2014;9(5):e96499.

26. Viret JF, Favre D, Wegmüller B, Herzog C, Que JU, Cryz SJ, et al. Mucosal and systemic
immune responses in humans after primary and booster immunizations with orally
administered invasive and noninvasive live attenuated bacteria. Infect Immun. 1999
Jul;67(7):3680–5.

27. Sears SD, Richardson K, Young C, Parker CD, Levine MM. Evaluation of the human
immune response to outer membrane proteins of Vibrio cholerae. Infect Immun. 1984
May;44(2):439–44.

28. Migasena S, Pitisuttitham P, Prayurahong B, Suntharasamai P, Supanaranond W, Desakorn
V, et al. Preliminary assessment of the safety and immunogenicity of live oral cholera
vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun. 1989 Nov;57(11):3261–
4.

29. Mascart-Lemone F, Carlsson B, Jalil F, Hahn-Zoric M, Duchateau J, Hanson LA. Polymeric
and monomeric IgA response in serum and milk after parenteral cholera and oral typhoid
vaccination. Scand J Immunol. 1988 Oct;28(4):443–8.

30. Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R, et al. Efficacy of
atovaquone/proguanil for malaria prophylaxis in children and its effect on the
immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis Off Publ Infect
Dis Soc Am. 2002 Nov 15;35(10):1147–54.

31. Chaicumpa W. Assessment of antibody responses and protective immunity in cholera
vaccinated subjects. 2018;

32. McCarty JM, Lock MD, Hunt KM, Simon JK, Gurwith M. Safety and immunogenicity of
single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
Vaccine. 2018 Feb 1;36(6):833–40.

33. McCarty JM, Lock MD, Bennett S, Hunt KM, Simon JK, Gurwith M. Age-related
immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a
randomized, controlled clinical trial. Vaccine. 2019 Mar 7;37(11):1389–97.

34. Bhuiyan MS, Hossain M, Sharmin S, Shirin A, Khanam F, Chowdhury F, et al. Assessment
of disease specific immune responses in enteric diseases using dried blood spot (DBS). PloS
One. 2019;14(6):e0218353.

35. Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M. Antibody-Based Correlates of
Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naïve Population.
Clin Vaccine Immunol CVI. 2017 May 31;24(8):e00098-17, CVI.00098-17.

36. Alam MM, Leung DT, Akhtar M, Nazim M, Akter S, Uddin T, et al. Antibody Avidity in
Humoral Immune Responses in Bangladeshi Children and Adults following Administration
of an Oral Killed Cholera Vaccine. Clin Vaccine Immunol CVI. 2013 Oct;20(10):1541–8.

37. Jertborn M, Svennerholm AM, Holmgren J. Evaluation of different immunization schedules
for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine.
1993;11(10):1007–12.

38. Kotloff KL, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM. Safety and
immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-

HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun. 1992 Oct;60(10):4430–2.

39. Jertborn M, Svennerholm AM, Holmgren J. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol. 1986 Aug;24(2):203–9.

40. McCarty JM, Cassie D, Bedell L, Lock MD, Bennett S. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2-5 Years in the United States. Am J Trop Med Hyg. 2020 Dec 14;104(3):861–5.

41. Adekunle O, Dretler A, Kauffman RC, Cho A, Rouphael N, Wrammert J. Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine. PLoS Negl Trop Dis. 2021 Sep 3;15(9):e0009743.

42. Chowdhury F, Akter A, Bhuiyan TR, Biswas R, Firoj MG, Tauheed I, et al. Long-term sialidase-specific immune responses after natural infection with cholera: Findings from a longitudinal cohort study in Bangladesh. Front Immunol [Internet]. 2022 Dec 22 [cited 2025 Jul 3];13. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1067737/full

43. Ateudjieu J, Sack DA, Nafack SS, Xiao S, Tchio-Nighie KH, Tchokomeni H, et al. An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon. Am J Trop Med Hyg. 2022 Nov 14;107(5):974–83.

44. Ng Ombe H, Simuyandi M, Mwaba J, Luchen CC, Alabi P, Chilyabanyama ON, et al. Immunogenicity and waning immunity from the oral cholera vaccine (ShancholTM) in adults residing in Lukanga Swamps of Zambia. PloS One. 2022;17(1):e0262239.

45. Islam MT, Date K, Khan AI, Bhuiyan TR, Khan ZH, Ahmed S, et al. Co-administration of Oral Cholera Vaccine With Oral Polio Vaccine Among Bangladeshi Young Children: A Randomized Controlled Open Label Trial to Assess Interference. Clin Infect Dis Off Publ Infect Dis Soc Am. 2023 Jan 13;76(2):263–70.

46. Kaisar MH, Bhuiyan MS, Akter A, Saleem D, Iyer AS, Dash P, et al. Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera. mSphere. 2021 Apr 28;6(2):e01232-20.

47. McCarty JM, Cassie D, Bedell L, Lock MD, Bennett S. Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States. Am J Trop Med Hyg. 2021 Apr 5;104(5):1758–60.

48. Su-Arehawaratana P, Singharaj P, Taylor DN, Hoge C, Trofa A, Kuvanont K, et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis. 1992 Jun;165(6):1042–8.

49. McCarty JM, Gierman EC, Bedell L, Lock MD, Bennett S. Safety and Immunogenicity of
Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years.
Am J Trop Med Hyg. 2020 Jan;102(1):48–57.

50. Rudin A, Johansson EL, Bergquist C, Holmgren J. Differential kinetics and distribution of
antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of
humans. Infect Immun. 1998 Jul;66(7):3390–6.

51. Dash P, Hakim A, Akter A, Banna HA, Kaisar MH, Aktar A, et al. Cholera toxin and O-
specific polysaccharide immune responses after oral cholera vaccination with Dukoral in
different age groups of Bangladeshi participants. mSphere. 2024 Mar 26;9(3):e0056523.